NO20044305L - Stabile farmasoytiske blandinger inneholdende faktor VIII - Google Patents

Stabile farmasoytiske blandinger inneholdende faktor VIII

Info

Publication number
NO20044305L
NO20044305L NO20044305A NO20044305A NO20044305L NO 20044305 L NO20044305 L NO 20044305L NO 20044305 A NO20044305 A NO 20044305A NO 20044305 A NO20044305 A NO 20044305A NO 20044305 L NO20044305 L NO 20044305L
Authority
NO
Norway
Prior art keywords
pharmaceutical compositions
compositions containing
factor viii
stable pharmaceutical
containing factor
Prior art date
Application number
NO20044305A
Other languages
English (en)
Other versions
NO328450B1 (no
Inventor
Mary White
Paul Webb
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Publication of NO20044305L publication Critical patent/NO20044305L/no
Publication of NO328450B1 publication Critical patent/NO328450B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
NO20044305A 2002-03-26 2004-10-11 Stabilt farmasøytisk preparat inneholdende faktor VIII NO328450B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0207092.8A GB0207092D0 (en) 2002-03-26 2002-03-26 Stable pharmaceutical composition containing factor VIII
PCT/GB2003/001297 WO2003080108A1 (en) 2002-03-26 2003-03-26 Stable pharmaceutical composition containing factor viii

Publications (2)

Publication Number Publication Date
NO20044305L true NO20044305L (no) 2004-10-11
NO328450B1 NO328450B1 (no) 2010-02-22

Family

ID=9933726

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044305A NO328450B1 (no) 2002-03-26 2004-10-11 Stabilt farmasøytisk preparat inneholdende faktor VIII

Country Status (27)

Country Link
US (1) US7790680B2 (no)
EP (2) EP2292216A3 (no)
JP (4) JP2005530714A (no)
KR (1) KR20040093482A (no)
CN (2) CN1642570B (no)
AR (1) AR039123A1 (no)
AT (1) ATE477814T1 (no)
AU (1) AU2003217030B2 (no)
BR (1) BR0308442A (no)
CA (1) CA2480226C (no)
DE (1) DE60333825D1 (no)
DK (1) DK1490095T3 (no)
ES (1) ES2350337T3 (no)
GB (1) GB0207092D0 (no)
HK (2) HK1080713A1 (no)
HR (1) HRP20040882B1 (no)
IL (2) IL163849A0 (no)
IS (1) IS7458A (no)
MX (1) MXPA04009275A (no)
MY (1) MY149831A (no)
NO (1) NO328450B1 (no)
NZ (1) NZ535032A (no)
PL (1) PL208009B1 (no)
PT (1) PT1490095E (no)
RU (1) RU2314825C2 (no)
TW (1) TWI285106B (no)
WO (1) WO2003080108A1 (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
RU2329823C2 (ru) * 2002-10-29 2008-07-27 Алза Корпорейшн Стабилизированные твердые полипептидные частицы
US7709224B2 (en) 2003-06-03 2010-05-04 Biosante Pharmaceuticals, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US7485291B2 (en) 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
WO2005047323A1 (en) * 2003-11-10 2005-05-26 Arriva-Prometic Inc. Dry recombinant human alpha 1-antitrypsin formulation
EP1750733B1 (en) 2004-05-03 2013-12-11 Emory University METHOD OF ADMINISTERING PORCINE B-DOMAINLESS fVIII
PL2268267T3 (pl) * 2008-04-21 2017-12-29 Novo Nordisk Health Care Ag Kompozycja sucha transglutaminazy
EP2113564A1 (en) 2008-05-01 2009-11-04 Arecor Limited Protein formulation
JP2012500250A (ja) 2008-08-21 2012-01-05 オクタファルマ アクチェン ゲゼルシャフト 組換えにより産生したヒト第ｖｉｉｉ及び第ｉｘ因子
JP5960990B2 (ja) * 2008-09-03 2016-08-02 オクタファルマ アクチェン ゲゼルシャフト 組み換え技術によって製造された第ｖｉｉｉ因子のための新規な保護組成物
JP5779780B2 (ja) 2008-11-07 2015-09-16 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 第ｖｉｉｉ因子製剤
GB0915480D0 (en) * 2009-09-04 2009-10-07 Arecor Ltd Stable formulation of factor viii
AU2011323236B2 (en) 2010-11-05 2017-03-30 Takeda Pharmaceutical Company Limited A new variant of antihemophilic factor VIII having increased specific activity
EP2970430A4 (en) * 2013-03-15 2017-01-11 Bayer HealthCare LLC Recombinant factor viii formulations
PL3666283T3 (pl) 2013-03-15 2022-10-03 Bioverativ Therapeutics Inc. Formulacje polipeptydu czynnika viii
BR112017002090B1 (pt) 2014-08-04 2021-06-01 Csl Limited Composição aquosa de fator viii de coagulação e método de estabilizar uma molécula de fviii
US20180200325A1 (en) * 2014-11-18 2018-07-19 Shionogi & Co., Ltd. Stabilized peptide composition
JP2022538357A (ja) 2019-07-04 2022-09-01 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 第ＶＩＩＩ凝固因子のｉｎ ｖｉｔｒｏでの安定性を向上させるための切断型フォン・ヴィレブランド因子（ＶＷＦ）
WO2022099223A2 (en) 2020-11-09 2022-05-12 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6281327A (ja) * 1985-10-04 1987-04-14 Green Cross Corp:The 人トロンビン製剤の加熱処理方法
JPS6485927A (en) * 1987-09-29 1989-03-30 Green Cross Corp Hepatitis b vaccine
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
WO1989009784A1 (en) * 1988-04-08 1989-10-19 Commonwealth Serum Laboratories Commission Production of heat-stable factor viii concentrate
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
IE64738B1 (en) * 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
DE4111393A1 (de) 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
SK282483B6 (sk) 1992-10-02 2002-02-05 Genetics Institute, Inc. Stabilná kompozícia koagulačného faktora VIII, spôsob jej prípravy a stabilizácie
SE9301581D0 (sv) 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
ZA955642B (en) * 1994-07-07 1997-05-06 Ortho Pharma Corp Lyophilized imaging agent formulation
JPH0899999A (ja) * 1994-09-30 1996-04-16 Chemo Sero Therapeut Res Inst α１プロテアーゼインヒビターの製造方法
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
CN101810854A (zh) * 1999-02-22 2010-08-25 巴克斯特国际公司 新的无白蛋白的因子viii制剂
CA2378751C (en) * 1999-07-13 2012-11-06 Biovitrum Ab Stable factor viii compositions
AU6558400A (en) * 1999-08-17 2001-03-13 Novo Nordisk A/S Stabilisation of freeze-dried cake
US6586574B1 (en) * 1999-08-17 2003-07-01 Nn A/S Stabilization of freeze-dried cake
US7282562B2 (en) * 1999-08-31 2007-10-16 Genentech, Inc. Compositions and methods for the treatment of immune related diseases

Also Published As

Publication number Publication date
NZ535032A (en) 2006-03-31
EP2292216A3 (en) 2011-05-11
CN1642570B (zh) 2013-01-09
EP1490095A1 (en) 2004-12-29
PL372414A1 (en) 2005-07-25
CA2480226C (en) 2012-09-18
NO328450B1 (no) 2010-02-22
HRP20040882B1 (hr) 2013-02-28
BR0308442A (pt) 2005-01-18
IL163849A (en) 2010-12-30
ATE477814T1 (de) 2010-09-15
MXPA04009275A (es) 2005-01-25
AU2003217030A1 (en) 2003-10-08
KR20040093482A (ko) 2004-11-05
CN103006540A (zh) 2013-04-03
TWI285106B (en) 2007-08-11
CN1642570A (zh) 2005-07-20
JP5770775B2 (ja) 2015-08-26
EP2292216A2 (en) 2011-03-09
ES2350337T3 (es) 2011-01-21
US20050256038A1 (en) 2005-11-17
RU2004131556A (ru) 2005-08-20
DK1490095T3 (da) 2010-11-08
WO2003080108A1 (en) 2003-10-02
AR039123A1 (es) 2005-02-09
IL163849A0 (en) 2005-12-18
JP2013147508A (ja) 2013-08-01
IS7458A (is) 2004-09-17
TW200304827A (en) 2003-10-16
PL208009B1 (pl) 2011-03-31
HK1080713A1 (en) 2006-05-04
MY149831A (en) 2013-10-31
CN103006540B (zh) 2015-09-16
EP1490095B1 (en) 2010-08-18
JP2015143245A (ja) 2015-08-06
JP2005530714A (ja) 2005-10-13
HRP20040882A2 (en) 2004-12-31
JP2011079862A (ja) 2011-04-21
GB0207092D0 (en) 2002-05-08
US7790680B2 (en) 2010-09-07
AU2003217030B2 (en) 2008-12-04
CA2480226A1 (en) 2003-10-02
RU2314825C2 (ru) 2008-01-20
DE60333825D1 (de) 2010-09-30
HK1183446A1 (en) 2013-12-27
PT1490095E (pt) 2010-10-21

Similar Documents

Publication Publication Date Title
DK1194161T3 (da) Stabile faktor VIII-sammensatninger
NO20044305L (no) Stabile farmasoytiske blandinger inneholdende faktor VIII
IS8460A (is) Lyfjafræðileg samsetning sem inniheldur kvetíapín
DK1459740T3 (da) Sammensætninger indeholdende sucralose
FI20011478A (fi) Farmaseuttinen koostumus
FI20105657A (fi) Farmaseuttisia koostumuksia
AR028204A1 (es) Composiciones farmaceuticas electrohiladas
ITMI20010748A0 (it) Composizioni farmaceutiche
DK1395242T3 (da) Flydende farmaceutisk sammensætning
ATE371456T1 (de) Pharmazeutische zusammensetzung enthaltend ein androgen
DK1458377T3 (da) Farmaceutiske sammensætninger indeholdende tegaserod
IS7051A (is) Lyfjasamsetningar
DK1587478T3 (da) Farmaceutisk sammensætning
NO20026123L (no) Farmasöytiske sammensetninger
DK1425005T3 (da) Farmaceutisk sammensætning indeholdende lumiracoxib
FI20022128A0 (fi) Farmaseuttinen koostumus
NO20031095D0 (no) Farmasöytiske sammensetninger
EP1480649A4 (en) STABLE PHARMACEUTICAL COMPOSITIONS
NO20044164L (no) Farmasoytiske sammensetninger
NO20042074L (no) Makrolider inneholdende farmasoytiske sammensetninger
ITMI20030705A1 (it) Composizione farmaceutica contenente n-acetil-l-cisteina
ITMI20020926A0 (it) Composizioni farmaceutiche riepitelizzanti
ITMI20021127A0 (it) Composizioni farmaceutiche oromucosali
DOP2002000508A (es) Composición farmaceutica
FI20031421A0 (fi) Uusia farmaseuttisia koostumuksia

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BAXALTA INCORPORATED, CH

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED, JP

CREP Change of representative

Representative=s name: BRYN AARFLOT AS, STORTINGSGATA 8, 0161 OSLO, NORGE

MK1K Patent expired